HLA-E and hematologic disorder: Monalizumab has already shown efficacy to strengthen NK cell responses against HLA-E overexpressing tumor cells in preclinical models [146], prompting its usage in various ongoing clinical trials including solid cancers and hematological malignancies (Clinical trial.gov).